GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » Profitability Rank

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Profitability Rank : 2 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Profitability Rank?

Corvus Pharmaceuticals has the Profitability Rank of 2. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Corvus Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Corvus Pharmaceuticals's Piotroski F-Score is 2.


Competitive Comparison of Corvus Pharmaceuticals's Profitability Rank

For the Biotechnology subindustry, Corvus Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corvus Pharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Profitability Rank falls into.



Corvus Pharmaceuticals Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Corvus Pharmaceuticals has the Profitability Rank of 2. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Corvus Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-6.253 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Corvus Pharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Corvus Pharmaceuticals Profitability Rank Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Corvus Pharmaceuticals (Corvus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
Executives
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
William Benton Jones officer: See Remarks 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Leiv Lea officer: Chief Financial Officer PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Miller Richard A Md director, officer: President and CEO PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell director 1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher officer: Chief Medical Officer 863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould director, 10 percent owner C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy officer: EVP Discovery Research CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt officer: SVP, Chief Business Officer 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner officer: V.P., Chemistry Research 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Headlines

From GuruFocus

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

By GuruFocusNews GuruFocusNews 06-19-2022